Abstract
Myelophil, a 30% ethanol extract that has an equal rate in both Astragali Radix and Salviae Radix, is a remedy for the treatment of fatigue-linked disorders in traditional Oriental medicine. The majority of patients with chronic fatigue have a risk of comorbidity with depression symptoms. To evaluate the anti-depressant activity of Myelophil, mice were subjected to unpredictable chronic mild stress (UCMS, eight different stresses) for 3 weeks with daily administration of distilled water, Myelophil (25, 50, or 100 mg/kg), or n-acetyl-l-cysteine (NAC) (100 mg/kg). After the final stress exposure, three behavioral tests, including the open field test (OFT), forced swimming test (FST), and tail suspension test (TST), and stress-derived alterations of the serotonergic signal and inflammatory response in the hippocampus were measured. UCMS notably induced depressive behaviors, whereas these behavioral alterations were significantly reversed by the administration of Myelophil in regard to the OFT, FST, and TST results. Myelophil also significantly attenuated the over-activation of microglial cells and the inflammatory response in the hippocampal region (TNF-α, tumor necrosis factor-alpha; IL-1β, interleukin-1beta; and caspase-1). Furthermore, Myelophil significantly restored the distortions of serotonergic function in the dorsal raphe nuclei and neurogenesis in the subgranular zone of the hippocampus. These results support the clinical relevance of the anti-depressant activity of Myelophil, specifically by modulating serotonergic function and the neuroinflammatory response.
Highlights
Depression, a pervasive emotional disorder, is the single largest contributor to the global burden of disease (WHO, 2017)
We found that Myelophil could alleviate the depressive-like behaviors via modulation of microglial-mediated neuroinflammation
Our findings are the first evidence of the antidepressant-like effects of Myelophil, which indicates the therapeutic possibilities on the mood disorders
Summary
Depression, a pervasive emotional disorder, is the single largest contributor to the global burden of disease (WHO, 2017). The number of patients who suffer from depressive disorder is estimated to be 322 million worldwide (WHO, 2017). The role of Nucleotide-binding oligomerization domain (NACHT), Leucine-rich repeat (LRR), and Pyrin domation (PYD) domains-containing protein 3 (NLRP3) inflammasome-dependent IL-1β has emerged as a novel contributor to depressive disorders (Alcocer-Gomez and Cordero, 2014; Kaufmann et al, 2017). These molecular alterations eventually led to impaired serotonergic synthesis and neurotransmission, which are characteristics of depression (Velasquez and Rappaport, 2016). Maintenance of serotonergic homeostasis is considered as a main strategy for psychiatric disorders (Nordquist and Oreland, 2010)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.